Table 2.

Calibration and Validation Results for the Model Proteins

					QC accuracy (%)/CV (%)
protein	matrix	LODa (ng/mL)	linearity range (ng/mL)	r2	low	medium	high
FcRn	rat liver	13.8	20–20 000	0.990	86.7/16.9	98.7/10.6	109/10.7
anti-HCV	rat plasma	25.2	40–40 000	0.995	97.6/11.3	93.5/15.6	91.8/13.6
cTnI	swine plasma	0.05b	0.1–100	0.991	86.6/20.3	118/13.8	98.2/10.6
IL-33	rat tumor	4.81	10–10 000	0.991	105/15.6	95.6/14.9	91.9/12.3
CD30	rat tumor	23.6	50–50 000	0.983	92.6/13.2	89.3/12.6	91.5/9.8
cT84.66	mouse tumor	20.9c	45–45 000	0.994	93.5/10.3	86.5/9.6	92.6/8.9
anti-TNFα	rat plasma	96.4d	150–150 000	0.989	85.2/18.6	91.5/13.5	97.2/10.2
CRP	human plasma	19.5	40–40 000	0.990	89.5/11.3	91.5/10.3	101/15.3
CEA	mouse tumor	34.6c	50–50 000	0.987	96.3/12.5	85.8/13.9	93.6/12.6
AB095	rat plasma	22.9	50–50 000	0.995	88.8/10.9	93.2/13.2	94.7/16.9

^aLimit of detection.

^bFor this target, antibody enrichment was used before digestion, and SPE enrichment was used after digestion.

^cSPE enrichment was used after digestion.

^dFor this antibody, no sensitive signature peptide was available.